Search Results

Gustavo Mahler hired as the Chief Executive Officer of Ncardia and of Cellistic, and will join the Board of Directors.

Ncardia announced today the appointment of Andy Holt as Chief Commercial Officer.

Ncardia has launched a new business, Cellistic™, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector.

Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes.

Ncardia announced today that following retraction of the Cor.4U product line from the market and resulting insolvency of its former legal entity in Germany (operating under the name Ncardia AG / former Axiogenesis), it has accelerated investment in its manufacturing site in Belgium, R&D and drug discovery center in the Netherlands, and commercial operations in the USA.

Under the terms of the agreement, Evotec has broad access to Ncardia’s stem cell derived cellular disease modelling IP.

Ncardia, a leader in human iPSC-based solutions for drug safety and efficacy screening, and Horizon Discovery Group plc (LSE:HZD) (Horizon), a global leader in gene editing and gene modulation technologies, announced a partnership to provide custom genetically modified and differentiated human iPSC-derived cells (hiPSC) for drug discovery researchers.